Study in progress - Pre-operative Oncotype DX testing: A decision impact study (PRE-DX)

Background: Oncotype DX Recurrence Score (RS) guides recommendations made to patients with ER+/HER2- breast cancer regarding post-surgery adjuvant therapy. Currently performed on the operative specimen following surgical treatment, it is technically possible and accurate to perform the Oncotype DX test on the diagnostic core biopsy (DCB). By eliminating the wait for surgical excision specimen RS results by testing the DCB, patients could be more accurately counselled regarding their treatment pathway and adjuvant treatments expedited allowing more efficient streaming of follow up appointments.